Related Experiment Video
Updated: May 25, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
[Clinical trial updates for malignant brain tumors]
1Department of Neurosurgery, Advanced Clinical Research Center at Nagoya University Graduate School of Medicine.
Rinsho Shinkeigaku = Clinical Neurology
|January 27, 2012
Summary
Interferon-beta (IFN-β) enhances temozolomide (TMZ) efficacy in glioma treatment by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT). Current genomic therapy trials explore siRNA-MGMT for improved patient survival.
Area of Science:
- Neuro-oncology
- Molecular biology
- Cancer genetics
Context:
- Gliomas are the most common primary brain tumors, with high-grade variants like glioblastoma multiforme (GBM) showing resistance to standard treatments.
- Temozolomide (TMZ) is a first-line therapy for malignant gliomas, but its effectiveness is significantly influenced by O(6)-methylguanine-DNA methyltransferase (MGMT) status.
- Previous in vitro studies indicated that Interferon-beta (IFN-β) enhances TMZ chemosensitivity by downregulating MGMT transcription.
Purpose:
- To investigate novel therapeutic strategies for malignant gliomas, focusing on enhancing the efficacy of existing treatments.
- To evaluate the potential of genomic therapy, specifically using siRNA targeting MGMT, as a next step following promising results from IFN-β gene therapy trials.
Summary:
- Interferon-beta (IFN-β) was shown to enhance temozolomide (TMZ) chemosensitivity in human glioma cells, likely through p53-induced downregulation of MGMT transcription.
- Clinical trials involving IFN-β gene therapy yielded reasonable safety and preliminary effectiveness.
- A current clinical trial is investigating genomic therapy with siRNA targeting MGMT to improve outcomes for GBM patients.
Impact:
- Potential for improved therapeutic strategies in neuro-oncology, particularly for treatment-resistant malignant gliomas.
- Development of targeted therapies that enhance the effectiveness of standard chemotherapy agents like TMZ.
- Hope for prolonged survival and better tolerability in patients with glioblastoma multiforme through novel genomic approaches.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...